Latest From Danaher Corp.
Investors at Alliance for Regenerative Medicine’s Investor Day in March 2019 were bullish on cell and gene therapies, but some worry about the market overcrowding.
All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.
The proposed IPO for GE's healthcare business could be off the table, CEO Lawrence Culp said as GE announced plans to sell its biopharma business to Danaher for $21.4bn. The deal will provide the conglomerate with a much needed cash injection to handle its rising debts.
GE is replacing John Flannery as chairman and CEO with H. Lawrence Culp, formerly the chief of Danaher. But the change in leadership will not alter the company's previously announced plan to spin off GE Healthcare as a stand-alone business and make some other structural changes, the company says.
- In Vitro Diagnostics
- Medical Devices
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Beckman Coulter Inc.
- Genetix Group PLC
- Leica AG
- MDS Analytical Technologies
- Nobel Biocare Holding AG
- Pall Corp.
- Radiometer Medical APS
- Sybron Dental Specialties Inc.
- Senior Management
Thomas P Joyce, Jr., Pres. & CEO
Matt McGrew, EVP, CFO
Daniel A Raskas, SVP, Corp. Dev.
William H King, IV, SVP, Strategic Dev.
- Contact Info
Phone: (202) 828-0850
2200 Pennsylvania Ave. NW
Washington, DC 20037-1701
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.